The Life Sciences team advised Teva Pharmaceuticals on a $400 million strategic funding agreement with funds managed by Blackstone Life Sciences (“BXLS”) to support the continued clinical development of duvakitug. Additionally, under the terms of the agreement, BXLS will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future.
The Goodwin team was led by Jacqueline Mercier, Shane Albright, Sam Beavers, and Kingsley Taft.
For more information on the deal, please read the press release.